Abstract
A case of a patient with bronchioloalveolar cell predominate lung adenocarcinoma (BAC) studied using integrated Positron Emission Tomography and Computed Tomography (PET/CT) with both 18F-fluorodeoxyglucose ([18F]FDG-PET) and [11C]Choline ([11C]Choline-PET) is described, with the aim of evaluating a new non invasive imaging method to detect and stage BAC, and providing information on tumour biology in vivo. The information derived from combining the two tracers could help in distinguishing lung adenocarcinoma with large BAC components ([18F]FDG negative and [11C]Choline positive) from inflammatory lesion ([18F]FDG and [11C]Choline positive). In addition, the simultaneous use of two PET tracers, evaluating two different metabolic pathways, together with histopathologic, immunohistochemical and gene expression analysis, could help to improve understanding of tumour in vivo behaviour.
Keywords: Positron Emission Tomography, [11C]Choline, [18F]FDG, BAC, gene expression, lung cancer
Current Radiopharmaceuticals
Title: Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study
Volume: 1 Issue: 2
Author(s): Maria Picchio, C. Messa, B. Giglioni, F. Sanvito, E. Caporizzo, C. Landoni, G. Arrigoni, A. Carretta, R. Nicoletti, P. Zannini, A. Del Maschio and F. Fazio
Affiliation:
Keywords: Positron Emission Tomography, [11C]Choline, [18F]FDG, BAC, gene expression, lung cancer
Abstract: A case of a patient with bronchioloalveolar cell predominate lung adenocarcinoma (BAC) studied using integrated Positron Emission Tomography and Computed Tomography (PET/CT) with both 18F-fluorodeoxyglucose ([18F]FDG-PET) and [11C]Choline ([11C]Choline-PET) is described, with the aim of evaluating a new non invasive imaging method to detect and stage BAC, and providing information on tumour biology in vivo. The information derived from combining the two tracers could help in distinguishing lung adenocarcinoma with large BAC components ([18F]FDG negative and [11C]Choline positive) from inflammatory lesion ([18F]FDG and [11C]Choline positive). In addition, the simultaneous use of two PET tracers, evaluating two different metabolic pathways, together with histopathologic, immunohistochemical and gene expression analysis, could help to improve understanding of tumour in vivo behaviour.
Export Options
About this article
Cite this article as:
Picchio Maria, Messa C., Giglioni B., Sanvito F., Caporizzo E., Landoni C., Arrigoni G., Carretta A., Nicoletti R., Zannini P., Del Maschio A. and Fazio F., Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study, Current Radiopharmaceuticals 2008; 1 (2) . https://dx.doi.org/10.2174/1874471010801020062
DOI https://dx.doi.org/10.2174/1874471010801020062 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors
Current Topics in Medicinal Chemistry Indole Curcumin Reverses Multidrug Resistance by Reducing the Expression of ABCB1 and COX2 in Induced Multidrug Resistant Human Lung Cancer Cells
Letters in Drug Design & Discovery Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond
Current Drug Therapy Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Cancer Targeting Potential of Folate Targeted Nanocarrier under Comparative Influence of Tretinoin and Dexamethasone
Current Drug Delivery Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study
Recent Patents on Anti-Cancer Drug Discovery Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters New Targeted Therapies for Anaplastic Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology ICH Q8 Guidelines in Practice: Spray Drying Process Optimization by 2<sup>3</sup> Factorial Design for the Production of Famotidine Nanoparticles
Pharmaceutical Nanotechnology Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models
Anti-Cancer Agents in Medicinal Chemistry BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Neuro-endocrine Markers in Neoplasms. Diagnostic Interest and Future Prospects
Current Proteomics Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry